Sickle Cell Disease News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Ask Dr. Kevin: Understanding Clinical Trials and Sickle Cell Disease in the Black Community - Black Press USA



Black Press USA
 
Ask Dr. Kevin: Understanding Clinical Trials and Sickle Cell Disease in the Black Community 
Black Press USA
This article is the third installment in the ?Ask Dr. Kevin? series, brought to you by Pfizer Rare Disease in collaboration with the National Newspaper Publishers Association (NNPA) to increase understanding of sickle cell disease. Clinical trials are ...

 


Sickle Cell Disease Treatment Endari Soon to Be Available - Monthly Prescribing Reference



Sickle Cell Disease Treatment Endari Soon to Be Available 
Monthly Prescribing Reference
Emmaus Medical has announced that Endari (L-glutamine oral powder) will be available starting the week of Dec 17th through the specialty pharmacy, U.S. Bioservices. Endari was initially approved by the Food and Drug Administration (FDA) in July 2017 to ...

 


Intellia Therapeutics Announces New, Robust Genome Editing Data ... - GlobeNewswire (press release)



Pine Bluff Commercial
 
Intellia Therapeutics Announces New, Robust Genome Editing Data ... 
GlobeNewswire (press release)
ATLANTA, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using the CRISPR technology, and its collaborator, Novartis ...
Emmaus Medical, Inc. Announces Availability of Endari? for Treatment of Sickle Cell Disease Business Wire (press release)
UAPB grad hopes to treat sickle cell patients - News - Pine Bluff ... Pine Bluff Commercial
Intellia Therapeutics Announces New, Robust Genome Editing Data for Sickle Cell Disease at the American Society of ... Markets Insider

all 4 news articles » 


GBT Announces Presentation of Six Studies at ASH Supporting Voxelotor Sickle Cell Disease (SCD) Program - GlobeNewswire (press release)



EurekAlert
 
GBT Announces Presentation of Six Studies at ASH Supporting Voxelotor Sickle Cell Disease (SCD) Program 
GlobeNewswire (press release)
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced results from six data presentations, including a case study of seven patients with severe sickle cell disease (SCD) who ...
GBT Announces Presentation of Six Studies at ASH Supporting ... Nasdaq
Global Blood Therapeutics (GBT) Presents New Phase 2a Data at ... StreetInsider.com

all 7 news articles » 


Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of ... - PR Newswire (press release)



Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of ... 
PR Newswire (press release)
EAST HANOVER, N.J., Dec. 11, 2017 /PRNewswire/ -- Results from a post hoc subgroup analysis of the Phase II SUSTAIN study show that crizanlizumab, an investigational humanized anti-P-selectin monoclonal antibody, delayed the time to first sickle cell ...
Novartis (NVS) Reports Data from Phase II SUSTAIN Study Showing that Crizanlizumab Delayed the Time to First ... StreetInsider.com

all 1 news articles » 


Young man has coped with sickle cell disease his whole life - Magnoliareporter



Magnoliareporter
 
Young man has coped with sickle cell disease his whole life 
Magnoliareporter
Sickle cell disease, a hereditary blood disorder, affects about 100,000 Americans. In patients with sickle cell, some red blood cells become stiff and c-shaped like a sickle, instead of round. That makes it difficult for the cells to pass through tiny ...

 


Epizyme Presents Preclinical Data on Novel G9a Program and ... - GlobeNewswire (press release)



Epizyme Presents Preclinical Data on Novel G9a Program and ... 
GlobeNewswire (press release)
CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, announced today new preclinical data from its novel G9a program for sickle cell disease (SCD). The data ...
Epizyme (EPZM) Highlights Preclinical Data on Novel G9a Program ... StreetInsider.com
Epizyme Presents Preclinical Data on Novel G9a Program and Introduces Next Drug Development Candidate at the ... Nasdaq

all 1 news articles » 


GBT Announces New Phase 2a Data at ASH for Voxelotor in Adolescents with Sickle Cell Disease (SCD) - GlobeNewswire (press release)



GBT Announces New Phase 2a Data at ASH for Voxelotor in Adolescents with Sickle Cell Disease (SCD) 
GlobeNewswire (press release)
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced new results from its ongoing Phase 2a HOPE-KIDS 1 Study of once-daily oral therapy, voxelotor (previously called GBT440 ...

and more » 


Morgan Stanley: Global Blood Therapeutics 'Clearly Encouraged' By Sickle Cell Therapy Data - Benzinga



Benzinga
 
Morgan Stanley: Global Blood Therapeutics 'Clearly Encouraged' By Sickle Cell Therapy Data 
Benzinga
Global Blood's interim data for its Phase 2a trial of the sickle cell disease therapy GBT440 in adolescents was consistent with prior adult results and demonstrates efficacy on top of hydroxyurea and utility of the PRO, Harrison said in a Sunday note ...
Global Blood Therapeutics (GBT) Lowered to Sell at ValuEngine The Ledger Gazette
Global Blood Therapeutics Inc. (GBT) Reaches $41.05 After 9.00% Down Move; Upland Software (UPLD) SI Increased ... Frisco Fastball

all 21 news articles » 


Five Winners - And One Loser - From Medicine's Big Meeting About Blood - Forbes



Forbes
 
Five Winners - And One Loser - From Medicine's Big Meeting About Blood 
Forbes
Results were equally encouraging for a new manufacturing process for Blubird's treatment for beta thalassemia, another blood disease. All of three patients treated for more than six months were able to go without blood transfusions, and two had normal ...